FGFR2 and cholangiocarcinoma: This was followed by FIGHT-202, which was a multicenter, open-label, phase 2 trial enrolling 3 cohorts of patients with CCA who had progressed on prior treatment: those with FGFR2 fusion or rearrangement, those with FGFR2 mutation, and those with no alteration of FGFR2 [57].